Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Secures Additional $1.5M in Series B Round

NEW YORK, Oct. 17 – NimbleGen Systems has added $1.5 million in a second closing of its Series B financing round, the company said on Wednesday. A $9 million first closing was announced on Sept. 11, and the recent cash infusion brings to $14 million NimbleGen’s total funds raised to date.

NimbleGen, based in Madison, Wis., produces custom high-density DNA microarrays and is developing a desktop DNA microarray synthesizer based on its proprietary maskless array synthesizer technology, according to the company. MAS uses digital light processors to synthesize oligonucleotides in situ, the firm said.

In an e-mail this week, Mike Treble, NimbleGen’s CEO, said the company had begun shipping its arrays to collaborators. Last week he said NimbleGen expects to start delivering the first synthesizers within 18 months.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.